CoChat

Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study

Open access
Yao, Ming-yan, Li, Li-qin, Ma, Jian-xia, Xue, Peng, Li, Yu-kun · 2020 · Brazilian Journal of Medical and Biological Research
Cited by 13

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Glycemic variability (GV) may be linked to the development of diabetic complications by inducing inflammation, oxidative stress, and endothelial dysfunction. Flash glucose monitoring (FGM) provides a novel method of continuously monitoring interstitial glucose levels for up to 14 days. This study randomly assigned poorly controlled type 2 diabetes mellitus patients treated with metformin and multiple daily injections of insulin (n=60) to either continuous subcutaneous insulin infusion (CSII) treatment or CSII in combination with liraglutide (CSII+Lira) treatment for 14 days during hospitalization. GV was assessed using a FGM system; weight and cardiometabolic biomarkers were also evaluated. The coefficient of variation was significantly reduced in the CSII+Lira group (P<0.001), while no significant change was observed in the CSII group. The changes differed significantly between the two groups in mean amplitude of glycemic excursions (P=0.004), standard deviation (P=0.006), and the percentage of time in the target range (4-10 mmol/L, P=0.005 and >10 mmol/L, P=0.028). The changes in mean of daily differences, interquartile range, and percentage of time in hypoglycemia (<3.3 mmol/L) and hyperglycemia (>13.9 mmol/L) identified by FGM showed no difference. Treatment with liraglutide increased serum adiponectin [33.5 (3.5, 47.7) pg/mL, P=0.003] and heme oxygenase-1 levels [0.4 (-0.0, 1.8) ng/mL, P=0.001] and reduced serum leptin levels [-2.8 (3.9) pg/mL, P<0.001]. Adding the glucagon-like peptide-1 analog liraglutide improved GV, weight, and some cardiometabolic risk markers. The FGM system is, therefore, shown to be a novel and useful method for glucose monitoring.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1590/1414-431x20198652

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Research works printed but not linked: 24

  1. Dandona P, 2009, Insulin as an anti-inflammatory and antiatherogenic modulator, J Am Coll Cardiol, 53, S14, 10.1016/j.jacc.2008.10.038 · DOI · Paper page
  2. 1998, UK Prospective Diabetes Study (UKPDS) Group, Lancet, 352, 837
  3. Holman RR, 2008, 10-year follow-up of intensive glucose control in type 2 diabetes, N Engl J Med, 359, 1577, 10.1056/NEJMoa0806470 · DOI · Paper page
  4. Zhang S, 2012, Skimmin, a coumarin, suppresses the streptozotocin-induced diabetic nephropathy in wistar rats, Eur J Pharmacol, 692, 78, 10.1016/j.ejphar.2012.05.017 · DOI
  5. Kramer CK, 2013, Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis, Lancet Diabetes Endocrinol, 1, 28, 10.1016/S2213-8587(13)70006-8 · DOI · Paper page
  6. Lee MK, 2017, Impact of initial active engagement in self-monitoring with a telemonitoring device on glycemic control among patients with type 2 diabetes, Sci Rep, 7, 3866, 10.1038/s41598-017-03842-2 · DOI
  7. Thompson B, 2018, An overview of safety issues on use of insulin pumps and continuous glucose monitoring systems in the hospital, Curr Diab Rep, 18, 81, 10.1007/s11892-018-1056-7 · DOI
  8. Gerstein HC, 2008, Effects of intensive glucose lowering in type 2 diabetes, N Engl J Med, 358, 2545, 10.1056/NEJMoa0802743 · DOI · Paper page
  9. Duckworth W, 2009, Glucose control and vascular complications in veterans with type 2 diabetes, N Engl J Med, 360, 129, 10.1056/NEJMoa0808431 · DOI · Paper page
  10. Monnier L, 2006, Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes, JAMA, 295, 1681, 10.1001/jama.295.14.1681 · DOI · Paper page
  11. Sato T, 2019, Accuracy of flash glucose monitoring in insulin-treated patients with type 2 diabetes, J Diabetes Investig, 10, 846, 10.1111/jdi.12954 · DOI
  12. Maiorino MI, 2018, The effects of subcutaneous insulin infusion versus multiple insulin injections on glucose variability in young adults with type 1 diabetes: the 2-year follow-up of the observational METRO study, Diabetes Technol Ther, 20, 117, 10.1089/dia.2017.0334 · DOI
  13. Ajjan RA, 2019, Optimising use of rate-of-change trend arrows for insulin dosing decisions using the FreeStyle Libre flash glucose monitoring system, Diab Vasc Dis Res, 16, 3, 10.1177/1479164118795252 · DOI
  14. Reddy M, 2018, Switching from flash glucose monitoring to continuous glucose monitoring on hypoglycemia in adults with type 1 diabetes at high hypoglycemia risk: the extension phase of the I HART CGM study, Diabetes Technol Ther, 20, 751, 10.1089/dia.2018.0252 · DOI · Paper page
  15. Zhou BF, 2002, Predictive values of body mass index and waist circumference for risk factors of certain related diseases in Chinese adults - study on optimal cut-off points of body mass index and waist circumference in Chinese adults, Biomed Environ Sci, 15, 83
  16. Costantino S, 2017, Impact of glycemic variability on chromatin remodeling, oxidative stress, and endothelial dysfunction in patients with type 2 diabetes and with target HbA1c levels, Diabetes, 66, 2472, 10.2337/db17-0294 · DOI · Paper page
  17. Ajjan RA, 2017, How can we realize the clinical benefits of continuous glucose monitoring?, Diabetes Technol Ther, 19, S27, 10.1089/dia.2017.0021 · DOI · Paper page
  18. Lane W, 2014, The effect of addition of liraglutide to high-dose intensive insulin therapy: a randomized prospective trial, Diabetes Obes Metab, 16, 827, 10.1111/dom.12286 · DOI · Paper page
  19. Pokala N, 2017, The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin, Diabetes Obes Metab, 19, 1454, 10.1111/dom.12939 · doi:10.1111/dom.12939
  20. Farr OM, 2016, Short-term administration of the GLP-1 analog liraglutide decreases circulating leptin and increases GIP levels and these changes are associated with alterations in CNS responses to food cues: A randomized, placebo-controlled, crossover study, Metabolism, 65, 945, 10.1016/j.metabol.2016.03.009 · DOI · Paper page
  21. Li D, 2015, Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes, Diabetes Res Clin Pract, 110, 224, 10.1016/j.diabres.2015.05.051 · DOI
  22. Kim Chung le T, 2009, Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression, Biochem Biophys Res Commun, 390, 613, 10.1016/j.bbrc.2009.10.015 · DOI · Paper page
  23. Oeseburg H, 2010, Glucagon-like peptide 1 prevents reactive oxygen species-induced endothelial cell senescence through the activation of protein kinase A, Arterioscler Thromb Vasc Biol, 30, 1407, 10.1161/ATVBAHA.110.206425 · DOI · Paper page
  24. Sen Z, 2019, Coumarin glycosides from Hydrangea paniculata slow down the progression of diabetic nephropathy by targeting Nrf2 anti-oxidation and smad2/3-mediated profibrosis, Phytomedicine, 57, 385, 10.1016/j.phymed.2018.12.045 · doi:10.1016/j.phymed.2018.12.045

Cited by

See all 13

Metadata

Authors
Yao, M.-Y., Li, L.-Q., Ma, J.-X., Xue, P., & Li, Y.-K.
Venue
Brazilian Journal of Medical and Biological Research
Published
2020-01
Volume
53
Issue
1
Pages
e8652-e8652
ISSN
  • 0100-879X (ISSN-L)
  • 1414-431X
OpenAlex
W2994638108
Cited by
13
References
10
FWCI
0.52
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study. https://app.cochat.ai/papers/10.1590/1414-431x20198652
The paper
Yao, M.-Y., Li, L.-Q., Ma, J.-X., Xue, P., & Li, Y.-K. (2020). Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study. Brazilian Journal of Medical and Biological Research. https://doi.org/10.1590/1414-431x20198652

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.